Format

Send to

Choose Destination
PLoS One. 2015 Mar 5;10(3):e0118646. doi: 10.1371/journal.pone.0118646. eCollection 2015.

An anti-ubiquitin antibody response in transitional cell carcinoma of the urinary bladder.

Author information

1
Department of Urology, University Hospital Basel, Basel, Switzerland; Department of Urology and Pediatric Urology, Medical School, Albert-Ludwigs-University of Freiburg, Freiburg, Germany; Department of Urology, Bavarian Julius Maximilians-University Medical School, Würzburg, Germany.
2
Department of Urology, University Hospital Basel, Basel, Switzerland.
3
Department of Urology and Pediatric Urology, Medical School, Albert-Ludwigs-University of Freiburg, Freiburg, Germany.
4
Center for Thrombosis and Hemostasis, Johannes Gutenberg University Medical Center Mainz, Mainz, Germany.
5
Division of Hematology/Oncology and Division of Molecular Medicine, Department of Internal Medicine, University of New Mexico School of Medicine, Albuquerque, New Mexico, United States of America.
6
Department of Urology, Bavarian Julius Maximilians-University Medical School, Würzburg, Germany.

Abstract

BACKGROUND:

To use combinatorial epitope mapping ("fingerprinting") of the antibody response to identify targets of the humoral immune response in patients with transitional cell carcinoma (TCC) of the bladder.

METHODS:

A combinatorial random peptide library was screened on the circulating pool of immunoglobulins purified from an index patient with a high risk TCC (pTa high grade plus carcinoma in situ) to identify corresponding target antigens. A patient cohort was investigated for antibody titers against ubiquitin.

RESULTS:

We selected, isolated, and validated an immunogenic peptide motif from ubiquitin as a dominant epitope of the humoral response. Patients with TCC had significantly higher antibody titers against ubiquitin than healthy donors (p<0.007), prostate cancer patients (p<0.0007), and all patients without TCC taken together (p<0.0001). Titers from superficial tumors were not significantly different from muscle invasive tumors (p = 0.0929). For antibody response against ubiquitin, sensitivity for detection of TCC was 0.44, specificity 0.96, positive predictive value 0.96 and negative predictive value 0.41. No significant titer changes were observed during the standard BCG induction immunotherapy.

CONCLUSIONS:

This is the first report to demonstrate an anti-ubiquitin antibody response in patients with TCC. Although sensitivity of antibody production was low, a high specificity and positive predictive value make ubiquitin an interesting candidate for further diagnostic and possibly immune modulating studies.

PMID:
25742283
PMCID:
PMC4351094
DOI:
10.1371/journal.pone.0118646
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Public Library of Science Icon for PubMed Central
Loading ...
Support Center